Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i wt » _ wt (Expand Search), i w (Expand Search), i et (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i wt » _ wt (Expand Search), i w (Expand Search), i et (Expand Search)
-
981
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
982
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
983
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
984
-
985
-
986
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
987
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
988
-
989
-
990
-
991
-
992
-
993
-
994
-
995
-
996
-
997
-
998
-
999
-
1000